Reuters: Regulatory News: UK cost agency backs Astra, Bristol diabetes drug in some cases

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UK cost agency backs Astra, Bristol diabetes drug in some cases May 29th 2013, 23:01 LONDON | Wed May 29, 2013 7:01pm EDT LONDON May 30 (Reuters) - Britain's healthcare cost watchdog NICE is recommending a new diabetes drug from Bristol-Myers Squibb and AstraZeneca in some circumstances, marking a change of tack following an earlier blanket rejection. The National Institute for Health and Clinical Excellence (NICE) said on Thursday that Forxiga, or dapagliflozin, was a cost-effective option for type 2 diabetes when used in combination with the older medicine metformin. However, the final draft guidance still does not recommend Forxiga as a triple therapy in combination with metformin and sulfonylurea, another blood-sugar-lowering drug. The agency changed its position on the drug after requesting further information from its manufacturers. NICE decides if drugs should be paid for on the state health service and its decisions are followed closely both by drug companies and health authorities in other countries. NICE said it expected to publish final guidance on Forxiga in June 2013.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions